Document is current

Article History

Accepted: 26 July 2023

First Online: 14 August 2023

Change Date: 3 September 2023

Change Type: Update

Change Details: SMC was supported by a Medical Research Council grant, MC_UU_00004/03.

Declarations

:

: NN is a full-time employee of ViiV Healthcare and holds GlaxoSmithKline stocks and shares. SMc reports grants from the European Union H2020 scheme, EDCTP 2, the National Institute of Health Research, and Gilead Sciences; other support from Gilead Sciences, and the Population Council Microbicide Advisory Board; and is Chair of the Project Advisory Committee for USAID grant awarded to CONRAD to develop tenofovir-based products for use by women (non-financial). The remaining authors have no competing interests to report.

: Ethical approval was granted by the London-Surrey Borders NHS Research Ethics Committee and approved by the Health Research Authority in 2017 (REC ref 17/LO/0625; IRAS project ID 224366). The study also gained ethical approval from the Royal Holloway University of London (RHUL) College Ethics Committee.

: Eligible participants were provided with a Participant Information Sheet, which provided information on the study, researcher contact details and intention to publish the findings. Written informed consent was then obtained from those who wished to participate by the research nurse or lead author (AT).